Inventor · disambiguated record
Thomas Gadek
Also filed as: GADEK THOMAS · GADEK THOMAS R · GADEK THOMAS RICHARD
67 granted patents·48 pending applications·5,184 citations·filing 1976–2025
99Inventor score
Top patents by PatentIndex Score
115 records- 0199US5049386AN-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses thereforSYNTEX INC·Filed 1990·Granted Sep 17, 1991·722 cites·8 claims
- 0299US4897355AN[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses thereforSYNTEX INC·Filed 1987·Granted Jan 30, 1990·1.9k cites·13 claims
- 0398US8168655B2Compositions and methods for treatment of eye disordersGADEK THOMAS·Filed 2006·Granted May 1, 2012·103 cites·19 claims
- 0498US5208036AN-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses thereforSYNTEX INC·Filed 1990·Granted May 4, 1993·406 cites·30 claims
- 0598US4946787AN-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses thereforSYNTEX INC·Filed 1989·Granted Aug 7, 1990·880 cites·8 claims
- 0697US9447077B2Crystalline pharmaceutical and methods of preparation and use thereofSARCODE BIOSCIENCE INC·Filed 2014·Granted Sep 20, 2016·40 cites·4 claims
- 0797US8592450B2Compositions and methods for treatment of eye disordersGADEK THOMAS·Filed 2012·Granted Nov 26, 2013·44 cites·22 claims
- 0897US8367701B2Crystalline pharmaceutical and methods of preparation and use thereofSARCODE BIOSCIENCE INC·Filed 2011·Granted Feb 5, 2013·63 cites·41 claims
- 0996US5545412AN-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses thereforSYNTEX INC·Filed 1995·Granted Aug 13, 1996·161 cites·4 claims
- 1095US8080562B2Crystalline pharmaceutical and methods of preparation and use thereofBURNIER JOHN·Filed 2009·Granted Dec 20, 2011·65 cites·21 claims
- 1194US6667318B2LFA-1 antagonist compoundsGENENTECH INC·Filed 2001·Granted Dec 23, 2003·65 cites·21 claims
- 1293US9045457B2Compositions and methods for treatmentSARCODE BIOSCIENCE INC·Filed 2013·Granted Jun 2, 2015·9 cites·20 claims
- 1393US6872735B2LFA-1 antagonist compoundsGENENTECH INC·Filed 2003·Granted Mar 29, 2005·51 cites·21 claims
- 1492US6313119B1Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesionAVENTIS PHARMA GMBH·Filed 2000·Granted Nov 6, 2001·32 cites·22 claims
- 1592US5366737AN-[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N,-tetrasubstituted ammonium lipids and uses thereforSYNTEX INC·Filed 1993·Granted Nov 22, 1994·36 cites·6 claims
- 1691US6340679B1Guanidine derivatives as inhibitors of cell adhesionAVENTIS PHARMA GMBH·Filed 2000·Granted Jan 22, 2002·48 cites·10 claims
- 1789US5565449ANonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptorGENENTECH INC·Filed 1995·Granted Oct 15, 1996·42 cites·7 claims
- 1889US5493007APlatelet aggregation inhibitors having high specificity for GPIIBIIIAGENENTECH INC·Filed 1994·Granted Feb 20, 1996·64 cites·4 claims
- 1988US2025011308A1Crystalline pharmaceutical and methods of preparation and use thereofBAUSCH & LOMB IRELAND LTD·Filed 2024·Application pending·0 cites
- 2087US6660728B2Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonistsAVENTIS PHARMA GMBH·Filed 2002·Granted Dec 9, 2003·30 cites·8 claims
- 2187US5403836ABenzazepine platelet aggregation inhibitors having specificity for the GPIIb IIIa receptorGENENTECH INC·Filed 1993·Granted Apr 4, 1995·34 cites·10 claims
- 2286US11028077B2Crystalline pharmaceutical and methods of preparation and use thereofNOVARTIS PHARMACEUTICALS CORP·Filed 2016·Granted Jun 8, 2021·3 cites·17 claims
- 2386US6723727B1Substituted purine derivatives, processes for their preparation, their use, and compositions comprising themHOECHST AG·Filed 2000·Granted Apr 20, 2004·26 cites·6 claims
- 2485US2023331711A1Crystalline pharmaceutical and methods of preparation and use thereofNOVARTIS PHARMACEUTICALS CORP·Filed 2023·Application pending·0 cites
- 2584US8871935B2Crystalline pharmaceutical and methods of preparation and use thereofSARCODE BIOSCIENCE INC·Filed 2012·Granted Oct 28, 2014·4 cites·3 claims
- 2684US5550289AN-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses thereforSYNTEX INC·Filed 1995·Granted Aug 27, 1996·58 cites·13 claims
- 2782US6005117AImino compounds, process for their preparation and their use as victronectin antagonistsHOECHST AG·Filed 1997·Granted Dec 21, 1999·59 cites·17 claims
- 2881US6743800B1Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising themAVENTIS PHARMA GMBH·Filed 2000·Granted Jun 1, 2004·18 cites·9 claims
- 2980US6747016B1Substituted purine derivatives as inhibitors of cell adhesionAVENTIS PHARMA GMBH·Filed 2000·Granted Jun 8, 2004·14 cites·8 claims
- 3078US10960087B2Compositions and methods for treatment of diabetic retinopathyNOVARTIS AG·Filed 2015·Granted Mar 30, 2021·2 cites·18 claims
- 3178US6482821B2Vitronectin receptor antagonists, their preparation and their useHOECHST AG·Filed 2001·Granted Nov 19, 2002·8 cites·9 claims
- 3277US6399620B1Cycloalkyl derivatives as inhibitors of bone resporption and vitronectin receptor antagonistsHOECHST AG·Filed 2000·Granted Jun 4, 2002·8 cites·14 claims
- 3376US4104308ASynthesis of squaric acidIBM·Filed 1976·Granted Aug 1, 1978·12 cites·5 claims
- 3476US2022073500A1Crystalline pharmaceutical and methods of preparation and use thereofNOVARTIS PHARMACEUTICALS CORP·Filed 2021·Application pending·0 cites
- 3575US6387395B1N-[1, (1-1) -dialkyloxy] - and N- [1, (1-1) -dialkenyloxy]- alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses thereforFiled 1994·Granted May 14, 2002·31 cites·26 claims
- 3674US6344439B1Agents for promoting bone formationAVENTIS PHARMA SA·Filed 2000·Granted Feb 5, 2002·6 cites·1 claims
- 3773US10188641B2Compositions and methods for treatmentSARCODE BIOSCIENCE INC·Filed 2013·Granted Jan 29, 2019·0 cites·20 claims
- 3872US6387895B1Vitronectin receptor antagonists, their preparation and their useHOECHST AG·Filed 2001·Granted May 14, 2002·4 cites·10 claims
- 3971US6747148B2Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesionHOECHST MARION ROUSSEL DE GMBH·Filed 2001·Granted Jun 8, 2004·4 cites·6 claims
- 4070US2017143691A1Compositions and methods for treatmentSARCODE BIOSCIENCE INC·Filed 2016·Application pending·0 cites
- 4170US2017143693A1Compositions and methods for treatmentSARCODE BIOSCIENCE INC·Filed 2016·Application pending·0 cites
- 4270US2014099387A1Compositions and methods for treatmentSARCODE BIOSCIENCE INC·Filed 2013·Application pending·0 cites
- 4370US2017143690A1Compositions and methods for treatmentSARCODE BIOSCIENCE INC·Filed 2016·Application pending·0 cites
- 4470US2017143692A1Compositions and methods for treatmentSARCODE BIOSCIENCE INC·Filed 2016·Application pending·0 cites
- 4570US2014073666A1Compositions and methods for treatmentSARCODE BIOSCIENCE INC·Filed 2013·Application pending·0 cites
- 4669US5674863ANonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptorGENENTECH INC·Filed 1995·Granted Oct 7, 1997·11 cites·7 claims
- 4769US5663166ANonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptorGENENTECH INC·Filed 1995·Granted Sep 2, 1997·11 cites·7 claims
- 4868US2025222070A1Stable peptide compositionsTEARSOLUTIONS INC·Filed 2024·Application pending·0 cites
- 4966US5674865ANonpeptidyl integrin inhibitors having specificity for the GPIIb IIIaGENENTECH INC·Filed 1995·Granted Oct 7, 1997·9 cites·7 claims
- 5066US5250679ANonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptorGENENTECH INC·Filed 1992·Granted Oct 5, 1993·19 cites·1 claims
Showing the top 50 of 115 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →